EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Successful transition from rhPTH(1-84) to palopegteriparatide in chronic hypoparathyroidism

Isabella Chiardi iD, Pierpaolo Trimboli iD

JCEM Case Reports · 19.03.2026 · 4 (4)

DOI: 10.1210/jcemcr/luag048 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 26.03.2026. Verfasst von Isabella Chiardi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Therapeutics, University of Pavia, Pavia 27100, Italy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoparathyroidism management has advanced in recent decades, particularly for patients unresponsive to conventional therapy. Several parathyroid hormone–based agents have been developed to better imitate physiologic hormone replacement. Recombinant human parathyroid hormone (1-84) [rhPTH(1-84), Natpar®] was approved as an adjunct to calcium and vitamin D for chronic hypoparathyroidism but was later withdrawn, with global production ceasing in 2024. Palopegteriparatide (Yorvipath®; TransCon PTH), a long-acting parathyroid hormone (1-34) prodrug recently approved, represents a new-generation replacement therapy. Transitioning patients from rhPTH(1-84) to palopegteriparatide is increasingly relevant but remains scarcely documented, with only a single real-world report available. We describe a patient with chronic postsurgical hypoparathyroidism after total thyroidectomy who continued to experience symptoms despite conventional therapy. rhPTH(1-84) initially improved symptoms and stabilized calcium levels, but additional supplementation became necessary over time. In September 2024, ahead of rhPTH(1-84) withdrawal, therapy was switched to palopegteriparatide, allowing gradual dose titration and complete withdrawal of calcium and magnesium supplements. The patient maintained stable biochemical values and reported improved well-being, with no adverse events. This case supports the effective transition from rhPTH(1-84) to palopegteriparatide, restoring biochemical stability and independence from conventional therapy.

Schlagwörter

Stichwörter der Autor:innen

TransCon PTHYorvipathhypoparathyroidismpalopegteriparatiderhPTH (1-84)therapy transition

Autor:innen und Institutionen

  • Department of Internal Medicine and Therapeutics, University of Pavia, Pavia 27100, Italy.
  • Thyroid Unit, Clinic for Endocrinology and Diabetology, Ente Ospedaliero Cantonale (EOC), Bellinzona 6500, Switzerland.
  • Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano 6900, Switzerland.

ORCID-Profile: Isabella Chiardi, Pierpaolo Trimboli

Zitieren

APA

Chiardi, I., & Trimboli, P. (2026). Successful transition from rhPTH(1-84) to palopegteriparatide in chronic hypoparathyroidism. JCEM Case Reports, 4(4). https://doi.org/10.1210/jcemcr/luag048

Vancouver

Chiardi I, Trimboli P. Successful transition from rhPTH(1-84) to palopegteriparatide in chronic hypoparathyroidism. JCEM Case Reports. 2026;4(4). doi:10.1210/jcemcr/luag048

BibTeX
@article{Chiardi2026,
  author = {Chiardi, Isabella and Trimboli, Pierpaolo},
  title = {Successful transition from rhPTH(1-84) to palopegteriparatide in chronic hypoparathyroidism},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {4},
  doi = {10.1210/jcemcr/luag048}
}
Kostenlos starten →